| |
CEBAM
|
ACP
|
HAS
|
KDIGO
|
KHA-CARI
|
BCMA
|
UMHS
|
VA-DoD
|
NICE
|
|---|
|
2012
|
2013
|
2013
|
2013
|
2013
|
2014
|
2014
|
2014
|
2015
|
|---|
|
Monitoring patients with known CKD
|
|
frequency (times /year)
|
|
G1/A1
|
1
| | |
1
| |
1
|
1
| |
≤1
|
|
G1/A2
|
1
| | |
1
| |
1
|
1
| |
1
|
|
G1/A3
|
1
| | |
2
| |
2
|
2
| |
≥1
|
|
G2/A1
|
1
| | |
1
| |
1
|
1
| |
≤1
|
|
G2/A2
|
1
| | |
1
| |
1
|
1
| |
1
|
|
G2/A3
|
2
| | |
2
| |
2
|
2
| |
≥1
|
|
G3a/A1
|
2
| | |
1
| |
1
|
1
| |
1
|
|
G3a/A2
|
2
| | |
2
| |
2
|
2
| |
1
|
|
G3a/A3
|
2
| | |
3
| |
3
|
3
| |
2
|
|
G3b/A1
|
2
| | |
2
| |
2
|
2
| |
≤2
|
|
G3b/A2
|
2
| | |
3
| |
3
|
3
| |
2
|
|
G3b/A3
|
≥4
| | |
3
| |
3
|
3
| |
≥2
|
|
G4/A1
|
≥4
| | |
3
| |
3
|
4**
| |
2
|
|
G4/A2
|
≥4
| | |
3
| |
3
|
3
| |
2
|
|
G4/A3
|
≥4
| | |
≥4
| |
≥4
|
≥4
| |
3
|
|
G5/A1
|
≥4
| | |
≥4
| |
≥4
|
≥4
| |
4
|
|
G5/A2
|
≥4
| | |
≥4
| |
≥4
|
≥4
| |
≥4
|
|
G5/A3
|
≥4
| | |
≥4
| |
≥4
|
≥4
| |
≥4
|
|
parameter
|
|
blood pressure
|
*
|
▪
|
▪
|
*
| |
▪
|
*
| |
*
|
|
weight
| | | | | |
▪
| | | |
|
(e)GFR
|
▪
|
▪
|
▪
|
▪
| |
▪
|
▪
| |
▪
|
|
albuminuria/proteinuria/ACR
|
▪
|
▪
|
▪
|
▪
| |
▪
|
▪
| |
▪
|
|
complete blood count
| | | | | |
▪
| | | |
|
iron saturation
| | | | | |
▪
| | | |
|
HbA1c
| | | | | |
▪
| | | |
|
serum calcium
| | | | | |
▪
| | | |
|
serum phosphorus
| | | | | |
▪
| | | |
|
serum potassium
| | | | | |
i
|
i
| | |
|
serum albumin
| | | | | |
▪
| | | |
|
complications
|
▪
| | | | | | | | |
|
inulin
| | | | | | | | |
i
|
|
51Cr-EDTA
| | | | | | | | |
i
|
|
125I-iothalamate
| | | | | | | | |
i
|
|
iohexol
| | | | | | | | |
i
|
|
cardiovascular risk
| | |
▪
| | |
▪➢
| | | |
|
smoking status
| | | | | |
▪
| | | |
|
medication
| |
▪
| | | |
▪
| | | |
|
psychosocial health
| | | | | |
▪
| | | |
- ▪ recommendation, − negative recommendation, i: when indicated, *not specifically mentioned, but obvious from the context (e.g. blood pressure targets), **probably transcription error, ➢ refers to British Columbian guideline “Cardiovascular disease - primary prevention”
- Stages of CKD: G1, glomerular filtration rate of ≥90 ml/min/1.73m2; G2, 60–89 ml/min/1.73m2; G3a, 45–59 ml/min/1.73m2; G3b, 30–44 ml/min/1.73m2; G4, 15–29 ml/min/1.73m2; G5, < 15 ml/min/1.73m2
- Albuminuria stages of CKD: A1, albumine-creatinine-ratio < 3 mg/mmol; A2, 3–30 mg/mmol; A3, > 30 mg/mmol
- ACR albumin-creatinine-ratio, eGFR estimated glomerular filtration rate, HbA1c glycated hemoglobin, 51Cr-EDTA chromium-51-ethylenediaminetetraacetic acid
- American College of Physicians (ACP), Belgisch Centrum voor Evidence Based Medicine (CEBAM), British Columbia Medical Association (BCMA), Department of Veteran’s Affairs (VA-DoD), Haute Autorité de Santé (HAS), Kidney Disease Improving Global Outcomes (KDIGO), Kidney Health Australia - Caring for Australasiansians with Renal Impairment (KHA-CARI), National Institute of Health and Care Excellence (NICE), University of Michigan Health System (UMHS)
